1435752-36-5

Basic information

• Product Name: ((1R,3R,5S)-5-acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl 4-nitrobenzoate
• Synonyms: ((1R,3R,5S)-5-acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl 4-nitrobenzoate
• CAS NO: 1435752-36-5
• Molecular Weight: 449.576
• Mol File: 1435752-36-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: ((1R,3R,5S)-5-acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl 4-nitrobenzoate(CAS DataBase Reference)
• NIST Chemistry Reference: ((1R,3R,5S)-5-acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl 4-nitrobenzoate(1435752-36-5)
• EPA Substance Registry System: ((1R,3R,5S)-5-acetoxy-3-(tert-butyldimethylsilyloxy)-2-methylenecyclopentyl)methyl 4-nitrobenzoate(1435752-36-5)

Safety Data

• Hazardous Substances Data: 1435752-36-5(Hazardous Substances Data)

Upstream product

• 637005-35-7 (3S,5R)-hept-1-en-6-yne-3,5-diol 
• 18162-48-6 tert-butyldimethylsilyl chloride 
• 1383812-06-3 (1S,2R,4R)-4-(tert-butyldimethylsilyloxy)-2-(hydroxymethyl)-3-methylenecyclopentyl acetate 
• 122-04-3 4-nitro-benzoyl chloride 
• 1383812-02-9 (1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-ynyl acetate 
• 1383811-98-0 (1S,3R)-3-(tert-butyldimethylsilyloxy)-1-(oxiran-2-yl)pent-4-yn-1-ol 
• 1383811-94-6 (3S,5R)-5-(tert-butyldimethylsilyloxy)hept-1-en-6-yn-3-ol 
• 1383811-90-2 (3S,5R)-5-(tert-butyldimethylsilyloxy)-7-(trimethylsilyl)hept-1-en-6-yn-3-ol 
• 1383811-86-6 (3S,5R)-7-(trimethylsilyl)hept-1-en-6-yne-3,5-diol 

Downstream Products

• 1435752-42-3 ((1R,3R,5S)-5-acetoxy-3-hydroxy-2-methylenecyclopentyl)methyl 4-nitrobenzoate 
• 1435752-48-9 ((1R,3S,5S)-5-acetoxy-3-(2-amino-6-chloro-9H-purin-9-yl)-2-methylenecyclopentyl)methyl 4-nitrobenzoate 
• 1435752-55-8 ((1R,3S,5S)-5-acetoxy-3-(2-amino-6-oxo-1H-purin-9(6H)-yl)-2-methylenecyclopentyl)methyl 4-nitrobenzoate 
• 142217-69-4 2-amino-9-[(1S,3R,4S)-4-hydroxy-3-(hydroxymethyl)-2-metylidenecyclopentyl]-3H-purin-6-one 
• 142217-69-4 entecavir 

Relevant articles and documents

Process for preparing entecavir and intermediates thereof

It comprises the preparation of entecavir of formula (I), or a pharmaceutically acceptable salt thereof, or a hydrate thereof by submitting a compound of formula (III) where X is an halogen selected from Cl, Br, and I, first to a hydrolysis reaction using formic acid and then to a deprotection reaction, and isolating the entecavir either as free base or as a pharmaceutically acceptable salt. It also comprises intermediates which intervene in this preparation process.

PROCESS FOR PREPARING AN ANTIVIRAL DRUG AND INTERMEDIATES THEREOF

Process for preparing an antiviral drug and intermediates thereof It comprises the preparation of entecavir of formula (I), or a pharmaceutically acceptable salt thereof, or a hydrate thereof by submitting a compound of formula (III) where X is an halogen selected from Cl, Br, and I, first to a hydrolysis reactionusing formic acid and then to a deprotection reaction, and isolating the entecavir either as free base or as a pharmaceutically acceptable salt. It also comprises intermediates which intervene in this preparation process.